Comments
Natco Pharma scrip gained nearly 3 per cent on Monday on Sofosbuvir generic launch in Nepal.
Natco shares were up 2.90 per cent or Rs 43.75 at Rs 1,552.80 on the BSE at 2.20 pm.
The Hyderabad-based company had annnouned that it launched the first generic version of Sofosbuvir in Nepal under its brand Hepcinat.
Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc., under its brand Sovaldi.
Natco priced its generic medicine at an MRP of Rs 19,900 for a bottle of 28 tablets in Nepal, according to a release.
"Natco hopes to launch the product in India soon subject to approval from the Drugs Controller General of India (DCGI),’’ the company said.
Natco had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.